Literature DB >> 11313890

Src family kinases and HER2 interactions in human breast cancer cell growth and survival.

A P Belsches-Jablonski1, J S Biscardi, D R Peavy, D A Tice, D A Romney, S J Parsons.   

Abstract

Evidence from murine fibroblast models and human breast cancer cells indicates that c-Src and human EGF receptor (HER1) synergize to enhance neoplastic growth of mammary epithelial cells. To investigate whether interactions between c-Src and other HER family members may also play a role in breast tumor progression, we characterized 13 human breast carcinoma cell lines and 13 tumor samples for expression of HER family members and c-Src and examined a subset of the cell lines for Src-dependent, heregulin (HRG)-augmented, anchorage-dependent and independent growth. By immunoblotting, we found that all cell lines overexpressed one or more HER family member, and 60% overexpressed c-Src. Seventy-five per cent of the tumor tissues overexpressed HER2, while 64% overexpressed c-Src. Colony formation in soft agar was enhanced by HRG in three of five cell lines tested, a response that correlated with the presence of a c-Src/HER2 heterocomplex. This result suggests that HRG may act through both HER2 and c-Src to facilitate anchorage-independent growth. In contrast, HRG had little effect on anchorage-dependent growth in any of the cell lines tested. PP1, a Src family kinase inhibitor, reduced or ablated HRG-dependent and independent soft agar growth or anchorage dependent growth, and triggered apoptosis in all cell lines tested. The apoptotic effect of PP1 could be partially or completely reversed by HRG, depending on the cell line. These results suggest that while Src family kinases may cooperate with HRG to promote the survival and growth of human breast tumor cells, they also function independently of HER2/HRG in these processes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313890     DOI: 10.1038/sj.onc.1204205

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

Review 1.  Differential regulation of EphA2 in normal and malignant cells.

Authors:  Jennifer Walker-Daniels; Angela R Hess; Mary J C Hendrix; Michael S Kinch
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

2.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.

Authors:  Semir Vranic; Zoran Gatalica; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-11       Impact factor: 2.967

3.  Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.

Authors:  Ke Liang; Francisco J Esteva; Constance Albarracin; Katherine Stemke-Hale; Yang Lu; Giampaolo Bianchini; Ching-Yi Yang; Yong Li; Xinqun Li; Chun-Te Chen; Gordon B Mills; Gabriel N Hortobagyi; John Mendelsohn; Mien-Chie Hung; Zhen Fan
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

4.  DHHC20: a human palmitoyl acyltransferase that causes cellular transformation.

Authors:  Jeremiah M Draper; Charles D Smith
Journal:  Mol Membr Biol       Date:  2010-04       Impact factor: 2.857

5.  Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.

Authors:  Wanping Xu; Xitong Yuan; Kristin Beebe; Zhexin Xiang; Len Neckers
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

6.  p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.

Authors:  Isabel Chu; Jun Sun; Angel Arnaout; Harriette Kahn; Wedad Hanna; Steven Narod; Ping Sun; Cheng-Keat Tan; Ludger Hengst; Joyce Slingerland
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

7.  Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor.

Authors:  Maria Loreto Bravo; Mauricio P Pinto; Ibeth Gonzalez; Barbara Oliva; Sumie Kato; Mauricio A Cuello; Carol A Lange; Gareth I Owen
Journal:  Endocrine       Date:  2014-05-23       Impact factor: 3.633

Review 8.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 9.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

10.  Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling.

Authors:  Jianping Zhao; Yongjun Zhang; Sujay Subbayya Ithychanda; Yizeng Tu; Ka Chen; Jun Qin; Chuanyue Wu
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.